登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 21 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 21
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
- 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
- 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心吉林大学第一医院First Hospital of Jilin University长春医院页面
- 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
- 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心武汉大学人民医院Renmin Hospital of Wuhan University武汉医院页面
- 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
- 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
- 研究中心浙江省人民医院Zhejiang Provincial People's Hospital杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06966700,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
入选标准第 6 条
Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory.
入选标准第 7 条
cT1c, N1-N2
入选标准第 2 条
cT2, N0-N2
入选标准第 3 条
cT3, N0-N2
入选标准第 4 条
cT4a-d, N0-N2
入选标准第 5 条
Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement
排除标准第 1 条
Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment.
排除标准第 3 条
Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1.
排除标准第 4 条
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137).
排除标准第 5 条
Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC).
排除标准第 6 条
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1).
入选标准第 8 条
Known additional malignancy that is progressing or has required active treatment within the past 5 years.
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06966700,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per AJCC 8th edition criteria as assessed by the physician investigator based on radiological and/or clinical assessment: cT1c, N1-N2 cT2, N0-N2 cT3, N0-N2 cT4a-d, N0-N2 The participant must have a centrally confirmed diagnosis of BC that is triple-negative or HR-low+/HER2- (defined as estrogen receptor (ER)-low+ expression in 1% to 10% cells and HER2- as by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Provides a core needle biopsy from the primary breast tumor at screening to the central laboratory. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1). Demonstrates adequate organ function.排除标准:Exclusion Criteria:
Metastatic (Stage IV) breast cancer or clinical node stage 3 (cN3) nodal involvement Has received any prior treatment, including radiation, systemic therapy,and/or definitive surgery for currently diagnosed breast cancer Has undergone excisional biopsy of the primary tumor, axillary lymph node dissection, and/or axillary sentinel lymph node biopsy prior to study treatment. Received prior systemic anticancer therapy including investigational agents within 4 weeks before C1D1. Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX- 40, CD137). Received prior treatment with a TROP2-targeted antibody-drug conjugate (ADC). Received prior treatment with a topoisomerase I inhibitor-containing ADC. Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Known additional malignancy that is progressing or has required active treatment within the past 5 years. Uncontrolled systemic disease. History of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening..
引自 ClinicalTrials.gov, NCT06966700, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06966700,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。